Related Experiment Video
Updated: Sep 20, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
SARS-CoV-2 Is Linked to Brain Volume Loss in Multiple Sclerosis
Tomas Uher1, Dominika Stastna1, Ingrid Menkyova1,2
1Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czechia.
Objective:
The impact of SARS-CoV-2 infection on brain and spinal cord pathology in patients with multiple sclerosis (pwMS) remains unclear. We aimed to describe changes in brain lesion activity and brain and spinal cord volumes following SARS-CoV-2 infection.
Methods:
We included 177 pwMS (570 MRI scans) diagnosed with and tested positive for SARS-CoV-2 infection between August 2020 and May 2021. All patients were free of clinical disease activity, disease-modifying therapy changes, and corticosteroids during the study. MRI scans were performed using a standardized protocol on a 3-Tesla scanner. We analyzed the effect of SARS-CoV-2 on brain lesion load accrual and brain and spinal cord volume measures using adjusted mixed-effect models.
Results:
During SARS-CoV-2 infection, patients had a median disease duration of 14.2 years, a median age of 44.9 years, and a median Expanded Disability Status Scale of 2.0. SARS-CoV-2 infection did not lead to any changes in the number or volume of T1 or T2 lesions in the brain. However, SARS-CoV-2 was associated with an increased whole brain (B = -0.17; SE = 0.08; p = 0.028), grey matter (B = -0.25; SE = 0.12; p = 0.040), and cortical grey matter volume loss (B = -0.32; SE = 0.13; p = 0.014). Greater ventricular enlargement following SARS-CoV-2 infection was evident only in individuals over the age of 40 (interaction of age vs. ventricular enlargement: B = 0.17; SE = 0.05; p = 0.0003). Only patients with more severe SARS-CoV-2 infection showed a reduction in mean upper cervical cord area (MUCCA) (B = 1.14; SE = 0.52; p = 0.030).
Interpretation:
SARS-CoV-2 infection in clinically stable pwMS was linked to increased neuronal tissue loss.
Insights
SARS-CoV-2 infection increased brain and spinal cord tissue loss in patients with multiple sclerosis (pwMS), particularly in those over 40. This study highlights potential long-term neurological effects of COVID-19 in pwMS.
Area of Science:
- Neurology
- Infectious Diseases
- Neuroimmunology
Background:
- The neurological impact of SARS-CoV-2 infection on patients with multiple sclerosis (pwMS) is not well understood.
- Investigating changes in brain and spinal cord pathology post-SARS-CoV-2 is crucial for managing pwMS.
Purpose of the Study:
- To assess the effects of SARS-CoV-2 infection on brain lesion activity and volumes in pwMS.
- To evaluate changes in spinal cord volume following SARS-CoV-2 infection in pwMS.
Main Methods:
- 177 pwMS with confirmed SARS-CoV-2 infection underwent MRI scans.
- Analysis focused on brain lesion load and brain/spinal cord volumes using mixed-effect models.
- Patients were clinically stable, without disease activity or recent treatment changes.
Main Results:
- SARS-CoV-2 infection did not alter brain lesion count or volume.
- Significant whole brain, grey matter, and cortical grey matter volume loss was observed.
- Ventricular enlargement occurred in pwMS over 40; reduced cervical cord area was seen in severe infections.
Conclusions:
- SARS-CoV-2 infection is associated with increased neuronal tissue loss in clinically stable pwMS.
- Age influences the extent of brain volume changes post-SARS-CoV-2.
- Severity of SARS-CoV-2 infection correlates with spinal cord volume reduction.
More Related Videos
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Neural Regulation
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Brain Imaging
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...

